Cultivated meat — real animal flesh grown from cells in bioreactors rather than from slaughtered animals — received its first regulatory approval in the United States in 2023. Since then, the technology has advanced faster than most observers expected while remaining further from mainstream commercial viability than its proponents initially hoped. Here is an honest assessment of where things stand.
The Technology Is Real and Working
Cultivated meat is produced by extracting a small sample of cells from a living animal — typically muscle stem cells, which have a high capacity for growth and differentiation — and placing them in a nutrient-rich growth medium inside a bioreactor. The cells multiply, differentiate, and form muscle tissue that is biologically identical to conventional meat.
The leading companies — UPSIDE Foods and GOOD Meat in the US, Mosa Meat in the Netherlands, and Aleph Farms in Israel — have all demonstrated commercially viable products. UPSIDE’s chicken has been served in limited-availability restaurant settings in San Francisco and Washington DC since late 2023. The meat is real chicken. It tastes like chicken. Independent chefs and food critics who have eaten it describe the taste and texture as indistinguishable from conventional chicken breast.
The Cost Problem Is Diminishing But Not Solved
The central challenge has always been cost. Early prototypes in 2013 cost approximately $300,000 per kilogram to produce. By 2024, leading producers had reduced production costs to roughly $15-25 per kilogram at pilot scale — still significantly above the $3-5 per kilogram that would be needed for mass market viability.
The cost reduction trajectory is steep, and most techno-economic analyses project that cultivated chicken and pork could reach price parity with conventional products in premium market segments by 2028-2030, assuming continued investment and scaling of bioreactor infrastructure.
The growth medium remains the primary cost driver. Cultured cells require amino acids, glucose, vitamins, and growth factors — historically derived from expensive foetal bovine serum (FBS). The shift to animal-free, recombinant growth media is now achievable but remains costlier than FBS alternatives at scale.
Regulatory Landscape
The US framework, established by a joint FDA-USDA agreement, requires cultivated meat to undergo pre-market safety consultation before sale. Both UPSIDE Foods and GOOD Meat have cleared this process for chicken. Singapore remains the only market with active commercial retail sales of cultivated meat products.
The European Union is proceeding with caution under its Novel Food framework, with approvals expected but likely years away. Several countries — including Italy, which passed a ban on cultivated meat production and sale in 2023 — have taken protectionist positions.
What It Means for Food Systems
The potential environmental implications are significant if the technology scales. Life-cycle analyses suggest cultivated meat could reduce land use by up to 95%, water use by up to 78%, and greenhouse gas emissions by 80-92% compared to conventional beef production. For chicken and pork, where conventional production is already more efficient, the environmental advantage is smaller but still substantial.
The practical reality is that cultivated meat is unlikely to replace conventional meat in the near term. The more plausible near-term scenario is a premium segment — marketed initially to consumers who are willing to pay more for environmental and animal welfare reasons — that expands as costs decline.
The question is not whether cultivated meat will exist commercially. It already does. The question is how quickly it can scale, and whether the industrial and regulatory infrastructure can be built fast enough to make it genuinely accessible before the window for meaningful climate impact closes.
